Drug Interactions in the Treatment of Malignancy in HIV-Infected Patients

Oncol Res Treat. 2017;40(3):120-127. doi: 10.1159/000458443. Epub 2017 Feb 24.

Abstract

The number of patients with HIV (human immunodeficiency virus) requiring treatment for malignancy is increasing worldwide. Concurrent treatment of HIV and malignancy is complicated by unpredictable drug-drug interactions, which can cause potentially life-threatening toxicities and ineffective treatment of either disease. This article aims to provide a practical approach to drug interactions and their management in this context to help deliver effective and safe treatment of both the malignancy and HIV.

Publication types

  • Review

MeSH terms

  • Anti-HIV Agents / administration & dosage*
  • Anti-HIV Agents / adverse effects*
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects*
  • Drug Interactions
  • Drug Therapy, Combination / adverse effects
  • Drug Therapy, Combination / methods
  • Drug Therapy, Combination / standards
  • Drug-Related Side Effects and Adverse Reactions / diagnosis
  • Drug-Related Side Effects and Adverse Reactions / etiology
  • Drug-Related Side Effects and Adverse Reactions / prevention & control*
  • Evidence-Based Medicine
  • HIV Infections / diagnosis
  • HIV Infections / drug therapy*
  • HIV Infections / etiology
  • Humans
  • Medical Oncology / standards
  • Neoplasms / diagnosis
  • Neoplasms / drug therapy*
  • Neoplasms / etiology
  • Practice Guidelines as Topic
  • Treatment Outcome

Substances

  • Anti-HIV Agents
  • Antineoplastic Agents